Kidney Cancer malady

MedlinePlus: You have two kidneys. they are fist-sized organs on either side of your backbone above your waist. the tubes inside filter and clean your blood, taking out waste products and making urine. kidney cancer forms in the lining of tiny tubes inside your kidneys. it happens most often in people over 40. risk factors include smoking, having certain genetic conditions and misusing pain medicines for a long time. often, kidney cancer doesn't have early symptoms. however, see your health care provider if you notice blood in your urine a lump in your abdomen unexplained weight loss pain in your side loss of appetite treatment depends on your age, your overall health and how advanced the cancer is. it might include surgery, radiation, chemotherapy or biologic therapy. biologic therapy boosts your body's own ability to fight cancer. nih: national cancer institute²³

MalaCards: Kidney Cancer, also known as renal cancer, is related to clear cell renal cell carcinoma and renal oncocytoma. An important gene associated with Kidney Cancer is SKCG-1 (sporadic kidney cancer gene 1), and among its related pathways are Pancreatic cancer and Signal transduction_PTEN pathway. The compounds egcg and threonine have been mentioned in the context of this disorder. Affiliated tissues include the kidney, kidney and prostate, and related mouse phenotypes are respiratory system and endocrine/exocrine gland.

Disease Ontology: A urinary system cancer that is located in the kidney.⁶

Wikipedia: Kidney cancer is a type of cancer that starts in the cells in the kidney.⁴⁴ more...

Aliases & Descriptions:

kidney cancer 6 30 17 8 23 renal cancer 6 30 32 malignant neoplasm of kidney except pelvis 6 malignant neoplasm of kidney 43 malignant tumour of kidney 6

renal cell carcinoma 1 30 renal adenocarcinoma 30 malignant neoplasms 43 renal cell cancer 30 hypernephroma 30

Diseases related to kidney cancer by text searches and GeneDecks gene sharing:

(show top 50)    (show all 953)

id	Related Disease	Score	Top Affiliating Genes
1	clear cell renal cell carcinoma	35.8	VHL, VEGFA, VEGFC, RASSF1, PAX2, MTOR
2	renal oncocytoma	35.2	VHL, SDHB, FLCN, FH, TP53
3	familial renal cell carcinoma	33.8	VHL, SDHB, FH, FHIT, DIRC2, RNF139
4	hereditary renal cell carcinoma	33.3	VHL, FHIT, COPS6, RNF139, TSC2
5	nasopharynx carcinoma	32.5	VEGFA, RASSF1, TP53, EGFR, C5orf4
6	tongue cancer	32.3	VHL, VEGFA, CDKN1A, FHIT, CA9, TP53
7	collecting duct carcinoma	31.8	VHL, PBRM1, FLCN, FHIT, MET, AMACR
8	renal clear cell carcinoma	30.9	RBX1, VHL, VEGFA, RASSF1, MTOR, FH
9	hereditary leiomyomatosis and renal cell cancer	30.9	SDHB, FH, HIF1A
10	cystic kidney	30.6	VHL, PAX2, FH, MAPK1, TSC1, TSC2
11	brain cancer	30.6	VEGFA, FH, ENO2, PTEN, EGFR
12	oral cavity cancer	30.2	VEGFA, GSTM1, GSTT1, MAPK14, TP53, EGFR
13	hemangioblastoma	30.1	VHL, VEGFA, FLT4, AQP1, ENO2, TP53
14	pancreatic cancer	29.8	VEGFA, CDKN1A, FHIT, MAPK1, PLAU, EGFR
15	cardia cancer	29.2	GSTM1, GSTP1, GSTT1, TP53
16	bronchogenic carcinoma	29.1	CDKN1A, GSTM3, IL2, IL2RB, ENO2, TP53
17	multinodular goiter	29.0	VHL, VEGFA, GNAS, CP
18	thrombocytosis	28.9	VEGFA, IFNA1, IFNA2, CXCL12, CSF2
19	leiomyomatosis	28.7	VHL, SDHB, FLCN, FH, TSC1, DES
20	paraganglioma	28.6	VHL, SDHB, FH, ENO2, PTEN, EGFR
21	non-hodgkin lymphoma	28.5	CDKN3, GSTM1, GSTT1, IL2, IL2RB, APAF1
22	angiomyolipoma	28.4	PAX2, MTOR, TP53, TNF, EGFR, TSC1
23	cervix carcinoma	28.4	CDKN1A, CDKN3, MET, TP53
24	proteinuria	28.3	VEGFA, PAX2, CD274, AQP1, FABP1, MAPK14
25	goiter	28.2	VHL, VEGFA, VEGFC, MET, IL2, GNAS
26	thyroid cancer, follicular	28.0	PIK3CA, RASSF1, CDKN1A, PTEN
27	polymyositis	28.0	VEGFA, CD274, IFNA1, IFNA2, TNF, DES
28	nephrotic syndrome	28.0	VEGFA, PAX2, MIF, GSTM1, GSTP1, GSTT1
29	immunodeficiency	27.9	PARK2, CD274, CDKN3, MIF, IL2, IL2RB
30	chromophobe renal cell carcinoma	27.9	VHL, PBRM1, FLCN, MET, RNF139, EGFR
31	nephritis	27.8	VEGFA, PAX2, MTOR, CDKN1A, CD274, MET
32	alveolar soft part sarcoma	27.8	MTOR, MET, ENO2, TP53, HIF1A, DES
33	neutropenia	27.7	IFNA1, IFNA2, TNF, EGFR, CXCL12, CXCR4
34	malignant peripheral nerve sheath tumor	27.6	MET, ENO2, TP53, EGFR, DES
35	vasculitis	27.6	VEGFA, VEGFC, MIF, IL2, IFNA1, IFNA2
36	hypoglycemia	27.6	VEGFA, CDKN3, MIF, ENO2, TNF, HIF1A
37	prostate carcinoma	27.5	VEGFA, GSTM1, GSTT1, TP53, PTEN, OGG1
38	thrombosis	27.5	VHL, VEGFA, IL2, IL2RB, MAPK10, IFNA1
39	sepsis	27.3	CDKN3, MIF, MAPK8, MAPK14, TNF, CXCL12
40	autoimmune thyroiditis	27.3	IL2, IL2RB, IFNA1, IFNA2, TP53, TNF
41	polycythemia	27.2	VHL, VEGFA, CDKN3, IFNA1, IFNA2, PLAUR
42	liver cancer	27.1	VEGFA, RASSF1, UBC, CDKN1A, CDKN3, FHIT
43	disseminated intravascular coagulation	27.0	VEGFA, MIF, IFNA1, IFNA2, TNF, CXCL12
44	verrucous carcinoma	27.0	CDKN1A, IFNA1, TP53, EGFR
45	multiple endocrine neoplasia	27.0	VHL, SDHB, UBC, JUND, CDKN1A, MAPK8
46	urinary bladder cancer	26.9	RASSF1, CDKN1A, GSTM1, GSTT1, TP53, TSC1
47	mucoepidermoid carcinoma	26.9	MAPK1, TP53, PTEN, EGFR, DES, CXCL12
48	large cell carcinoma	26.8	UCHL1, S100A7, ENO2, TP53, EGFR, CSF2
49	chordoma	26.8	VEGFA, CDKN3, MET, TP53, PTEN, PLAU
50	combined immunodeficiency	26.6	VHL, VEGFA, FHIT, IL2, IL2RB, TP53

Approved drugs:

Drug clinical trials:

MalaCards organs/tissues related to kidney cancer:

²²

FMA organs/tissues related to kidney cancer:

¹¹

MGI Mouse Phenotypes related to kidney cancer:

²⁵ (show all 26)

id	Description	MGI Source Accession	Score	Top Affiliating Genes
1	respiratory system phenotype	MP:0005388	10.1	EPAS1, EFS, TNS3, PBRM1, PARK2
2	endocrine/exocrine gland phenotype	MP:0005379	9.9	SPOP, TERF1, CA9, GNAS, APAF1, AQP1
3	craniofacial phenotype	MP:0005382	9.6	CSF2, TERF1, GNAS, MAPK8, APAF1
4	limbs/digits/tail phenotype	MP:0005371	9.2	GNAS, APAF1, MET, UCHL1, VEGFA, VHL
5	hematopoietic system phenotype	MP:0005397	9.1	TNS3, TENC1, COPS5, COPS6, TSC2, CSF2
6	liver/biliary system phenotype	MP:0005370	9.0	VHL, VEGFA, BAG3, JUND, MET, IL2
7	normal phenotype	MP:0002873	8.9	OGG1, TSC2, HIF1A, COPS5, TERF1, GNAS
8	embryogenesis phenotype	MP:0005380	8.5	COPS5, COPS6, NDUFA13, EGFR, CXCR4, CSF2
9	no phenotypic analysis	MP:0003012	8.5	PROM1, EGFR, TERF1, TP53, GNAS, MET
10	reproductive system phenotype	MP:0005389	8.4	TNF, TNS1, TENC1, PLIN2, TSC1, CSF2
11	renal/urinary system phenotype	MP:0005367	8.2	TNS1, TENC1, PTEN, DAPK1, EGFR, HIF1A
12	integument phenotype	MP:0010771	7.9	IL2RB, GNAS, TP53, TERF1, PLIN2, EGFR
13	digestive/alimentary phenotype	MP:0005381	7.6	TENC1, TERF1, PTEN, PLAU, EGFR, HIF1A
14	adipose tissue phenotype	MP:0005375	7.1	TNF, TENC1, PTEN, PLAU, PLIN2, EGFR
15	behavior/neurological phenotype	MP:0005386	6.8	MAPK10, MAPK1, GNAS, TNS1, PTEN, PLAUR
16	immune system phenotype	MP:0005387	6.8	APAF1, EGFR, PRKAB1, CSF2, ADPRH, EPAS1
17	skeleton phenotype	MP:0005390	6.8	PTEN, PLAU, EGFR, HIF1A, TSC1, CXCR4
18	vision/eye phenotype	MP:0005391	6.7	PLAU, PLIN2, EGFR, HIF1A, PRKAB1, PROM1
19	nervous system phenotype	MP:0003631	6.6	PLAUR, EGFR, HIF1A, TSC1, TSC2, PRKAB1
20	tumorigenesis	MP:0002006	5.5	PIK3CA, VHL, RASSF1, CDKN1A, FLCN, MIF
21	muscle phenotype	MP:0005369	5.1	PLAUR, PLAU, PTEN, TNF, TP53, EGFR
22	cardiovascular system phenotype	MP:0005385	4.2	PIK3CA, VHL, VEGFA, VEGFC, RASSF1, PBRM1
23	mortality/aging	MP:0010768	4.2	TSC2, DES, PRKAB1, CSF2, WIF1, EPAS1
24	growth/size phenotype	MP:0005378	3.3	MTOR, FABP2, MAPK8, MAPK14, MAPK1, AMACR
25	homeostasis/metabolism phenotype	MP:0005376	2.2	AQP1, TENC1, TERF1, PTEN, DAPK1, SPOP
26	cellular phenotype	MP:0005384	1.9	RALBP1, PARK2, PAX2, UNC5A, UNC5B, UNC5C

Articles related to kidney cancer:

(show top 50)    (show all 89)

id	Title	Authors	Year	Affiliating Genes
1	Identification of MAPK10 as a novel epigenetic marker for chromophobe kidney cancer. (21166945)	Yoo K.H.... Chang S.G.	2011	MAPK10
2	The glycolytic shift in fumarate-hydratase-deficient kidney cancer lowers AMPK levels, increases anabolic propensities and lowers ce llular iron levels. (21907923)	Tong W.H.... Rouault T.A.	2011	TP53, FH, PRKAB1
3	Impact of immunotherapy in metastatic kidney cancer in Germany after introduction of new target therapy--results of a telephone sur vey of the German Society of Immuno- and Targeted Therapy (DGFIT) (19937556)	Siebels M.... Heinzer H.	2010	IFNA1
4	Rlip76 transports sunitinib and sorafenib and mediate s drug resistance in kidney cancer. (19626587)	Singhal S.S.... Awasthi S.	2010	PIK3CA, RALBP1
5	Urinary biomarkers for the early diagnosis of kidney cancer. (20375178)	Morrissey J.J.... Kharasch E.D.	2010	AQP1, PLIN2
6	Screening for kidney cancer: is there a role for aqua porin-1 and adipophilin? (20435833)	Grebe S.K.... Erickson L.A.	2010	AQP1, PLIN2
7	Identification of alternatively spliced GRIM-19 mRNA in kidney cancer tissues. (20505682)	He X.... Cao X.	2010	NDUFA13
8	Molecular diagnosis and therapy of kidney cancer. (20059341)	Linehan W.M.... Srinivasan R.	2010	VHL
9	The genetic basis of kidney cancer: a metabolic disea se. (20448661)	Linehan W.M.... Schmidt L.S.	2010	TSC2, VHL, SDHB
10	Tensin3 is a negative regulator of cell migration and all four Tensin family members are downregulated in human kidney cancer. (19194507)	Martuszewska D.... Hafizi S.	2009	TENC1, TNS1, TNS3
11	High-dose intensity pulse interleukin-2 with famotidine in metastatic kidney cancer. (19409039)	Quan W.D.... Quan F.M.	2009	IL2
12	Hereditary kidney cancer: unique opportunity for dise ase-based therapy. (19402075)	Linehan W.M.... Srinivasan R.	2009	VHL, FH, FLCN
13	Systemic therapy of kidney cancer: tyrosine kinase in hibitors, antiangiogenesis or IL-2? (19663736)	Kirkali Z.... TA1zel E.	2009	VEGFA, IL2, IFNA1
14	Analysis of Drosophila segmentation network identifies a JNK pathway factor overexpressed in kidney cancer. (19164706)	Liu J.... White K.P.	2009	SPOP
15	Functional significance of Wnt inhibitory factor-1 ge ne in kidney cancer. (19887605)	Kawakami K.... Dahiya R.	2009	WIF1
16	RLIP76: a target for kidney cancer therapy. (19417134)	Singhal S.S.... Awasthi S.	2009	RALBP1
17	Antisense attenuation of p21 sensitizes kidney cancer to apoptosis in response to conventional DNA damaging chemotherapy associated with enhancement of phospho-p53. (18499163)	Park S.H.... Weiss R.H.	2008	CDKN1A
18	Low-dose cyclophosphamide and continuous-infusion interleukin-2 with famotidine in previously treated metastatic melanoma or kidney cancer. (18298334)	Quan W.D.... Walker P.R.	2008	IL2
19	Lymphangiogenesis in kidney cancer: expression of VEGF-C, VEGF-D and VEGFR-3 in clear cell and papillary renal cell carcinoma. (18813809)	Bierer S.... Wulfing C.	2008	FLT4, VEGFC, FIGF
20	Mechanisms of disease: hereditary leiomyomatosis and renal cell cancer--a distinct form of hereditary kidney cancer. (17287871)	Sudarshan S.... Linehan W.M.	2007	FH
21	Attenuation of PTEN increases p21 stability and cytosolic localization in kidney cancer cells: a potential mechanism of apoptosis resistance. (17300726)	Lin P.Y.... Weiss R.H.	2007	PTEN, CDKN1A, CDKN3
22	Hypoxia-inducible factor linked to differential kidney cancer risk seen with type 2A and type 2B VHL mutations. (17526729)	Li L.... Kaelin W.G.	2007	VHL, EPAS1
23	IL-2 signals through Sgk1 and inhibits proliferation and apoptosis in kidney cancer cells. (17571248)	Amato R.... Perrotti N.	2007	IL2, SGK1, IL2RB
24	Promoter hypermethylation profile of kidney cancer with new proapoptotic p53 target genes and clinical implications. (16951219)	Christoph F.... Schrader M.	2006	DAPK1, APAF1
25	Activating mutations of Gsalpha in kidney cancer. (16890646)	Kalfa N.... Sultan C.	2006	GNAS, EFS
26	Methylation of tumour suppressor genes APAF-1 and DAPK-1 and in vitro effects of demethylating agents in bladder and kidney cancer. (17133271)	Christoph F.... Schrader M.	2006	DAPK1, APAF1
27	Kidney cancer therapy: new perspectives and avenues. (17150003)	Alexandrescu D.T.... Dasanu C.A.	2006	MTOR
28	Second-line thalidomide/IL-2 therapy in metastatic kidney cancer--results of a pilot study (17099831)	Schrader A.J.... Hofmann R.	2006	IL2
29	Hypoxia-inducible factor determines sensitivity to inhibitors of mTOR in kidney cancer. (16341243)	Thomas G.V.... Sawyers C.L.	2006	HIF1A, MTOR
30	The role of carbonic anhydrase IX overexpression in kidney cancer. (16310354)	Dorai T.... Dutcher J.P.	2005	CA9
31	New treatments for metastatic kidney cancer. (15780170)	Mancuso A.... Sternberg C.N.	2005	VEGFA
32	Chemotherapies and immunotherapies for metastatic kidney cancer. (15610695)	Ko Y.J.... Atkins M.B.	2005	VEGFA
33	Prominin-1/CD133, a neural and hematopoietic stem cell marker, is expressed in adult human differentiated cells and certain types of kidney cancer. (15558321)	Florek M.... Corbeil D.	2005	PROM1
34	Continuous infusion interleukin-2 and antihistamines in metastatic kidney cancer. (16248764)	Walker P.R.... Quan W.D.	2005	IL2
35	The genetic basis of kidney cancer: why is tuberous sclerosis complex often overlooked? (15579029)	Henske E.P.	2004	TSC1, TSC2
36	Detection of promoter hypermethylation of tumor suppressor genes in urine from kidney cancer patients. (15251937)	Cairns P.	2004	VHL, RASSF1
37	Promoter hypermethylation profile of kidney cancer. (15217927)	Dulaimi E.... Cairns P.	2004	FH
38	Repeated cycles with 72-hour continuous infusion interleukin-2 in kidney cancer and melanoma. (15285881)	Quan W.... Burgess R.	2004	IL2
39	Phase II trial of tetrathiomolybdate in patients with advanced kidney cancer. (12738719)	Redman B.G.... Merajver S.D.	2003	CP
40	Bolus followed by continuous infusion interleukin-2 in patients with metastatic malignant melanoma and kidney cancer previously treated with interleukin-2. (14503947)	Quan W.D.... Quan F.M.	2003	IL2
41	Interleukin-2 based therapy for kidney cancer. (14650831)	Dutcher J.P.	2003	IL2
42	Promoter hypermethylation of tumor suppressor genes in urine from kidney cancer patients. (14695183)	Battagli C.... Cairns P.	2003	VHL, RASSF1
43	The von Hippel-Lindau protein, vascular endothelial growth factor, and kidney cancer. (12890838)	George D.J.... Kaelin W.G.	2003	VEGFA
44	Expression of the fragile histidine triad gene in normal rat tissues and human kidney cancer cell lines. (15080505)	Lee S.H.... Cho M.H.	2002	FHIT, ADPRH
45	Expression of the plasminogen activation system in kidney cancer correlates with its aggressive phenotype. (9563880)	Swiercz R.... Jankun J.	1998	PLAU, PLAUR
46	Kidney cancer. (9853456)	Vogelzang N.J.... Stadler W.M.	1998	IL2
47	Health related quality of life outcomes in patients treated for metastatic kidney cancer: a pilot study. (9112487)	Litwin M.S.... Belldegrun A.S.	1997	IL2
48	Somatic mutations of von Hippel-Lindau (VHL) tumor-suppressor gene in European kidney cancers. (7591282)	Bailly M.... Ozturk M.	1995	VHL
49	Treatment with tumor necrosis factor alpha and interferon alpha of a human kidney cancer xenograft in nude mice: evidence for an anticachectic effect of interferon alpha. (8166454)	Bassukas I.D.... Maurer-Schultze B.	1994	TNF, IFNA1
50	Immunotherapy of metastatic kidney cancer (8508201)	NAcgrier S.... Philip T.	1993	IL2, IFNA1

Genes related to kidney cancer according to GeneCards:

(show top 50)    (show all 96)

id	Symbol	Description	Score	GeneCards Section Context
1	SKCG-1	sporadic kidney cancer gene 1	11.0	Transcripts, Aliases & Descriptions
2	VHLL	von Hippel-Lindau tumor suppressor-like	11.0	Summaries
3	IFNA1	interferon, alpha 1	11.0	Publications
4	IL2	interleukin 2	11.0	Publications
5	ERVE-4	endogenous retrovirus group E, member 4	10.9	Publications
6	RNF139	ring finger protein 139	10.9	Publications
7	FH	fumarate hydratase	10.9	Publications
8	TENC1	tensin like C1 domain containing phosphatase (tensin 2)	10.9	Publications
9	NDUFA13	NADH dehydrogenase (ubiquinone) 1 alpha subcomplex, 13	10.9	Publications
10	VHL	von Hippel-Lindau tumor suppressor, E3 ubiquitin protein ligase	10.9	Publications
11	TNS4	tensin 4	10.9	Publications
12	FLCN	folliculin	10.9	Publications, Functions
13	PLIN2	perilipin 2	10.9	Publications
14	TCEB2	transcription elongation factor B (SIII), polypeptide 2 (18kDa, elongin B)	10.9	Publications
15	S100A7	S100 calcium binding protein A7	10.9	Publications
16	EFS	embryonal Fyn-associated substrate	10.9	Publications
17	C5orf4	chromosome 5 open reading frame 4	10.9
18	CA9	carbonic anhydrase IX	10.9	Publications
19	FIGF	c-fos induced growth factor (vascular endothelial growth factor D)	10.9	Publications
20	MOK	MOK protein kinase	10.9	Publications
21	JUND	jun D proto-oncogene	10.9	Publications
22	GSTM3	glutathione S-transferase mu 3 (brain)	10.9	Publications
23	RALBP1	ralA binding protein 1	10.9	Publications
24	FABP1	fatty acid binding protein 1, liver	10.9	Publications
25	UCHL1	ubiquitin carboxyl-terminal esterase L1 (ubiquitin thiolesterase)	10.9	Publications
26	UNC5A	unc-5 homolog A (C. elegans)	10.9	UniProt Related
27	BAG3	BCL2-associated athanogene 3	10.9	Publications
28	COPS6	COP9 constitutive photomorphogenic homolog subunit 6 (Arabidopsis)	10.9	Publications
29	AQP1	aquaporin 1 (Colton blood group)	10.9	Publications
30	AMACR	alpha-methylacyl-CoA racemase	10.9	Publications
31	WIF1	WNT inhibitory factor 1	10.9	Publications
32	SPOP	speckle-type POZ protein	10.9	Publications
33	UNC5B	unc-5 homolog B (C. elegans)	10.9	UniProt Related
34	PBRM1	polybromo 1	10.9	Publications
35	SDHB	succinate dehydrogenase complex, subunit B, iron sulfur (Ip)	10.9	Publications
36	MIF	macrophage migration inhibitory factor (glycosylation-inhibiting factor)	10.9	Publications
37	PHF17	PHD finger protein 17	10.9
38	RBX1	ring-box 1, E3 ubiquitin protein ligase	10.9	Publications
39	RASSF1	Ras association (RalGDS/AF-6) domain family member 1	10.9	Publications
40	TERF1	telomeric repeat binding factor (NIMA-interacting) 1	10.9	Publications
41	TNS1	tensin 1	10.9	Publications
42	TSC1	tuberous sclerosis 1	10.9	Publications
43	TSC2	tuberous sclerosis 2	10.9	Publications
44	PRKAB1	protein kinase, AMP-activated, beta 1 non-catalytic subunit	10.9	Publications
45	IL2RB	interleukin 2 receptor, beta	10.9	Publications
46	CD274	CD274 molecule	10.9	Publications
47	FABP2	fatty acid binding protein 2, intestinal	10.9	Publications
48	EPAS1	endothelial PAS domain protein 1	10.9	Publications
49	ADPRH	ADP-ribosylarginine hydrolase	10.9	Publications
50	COPS5	COP9 constitutive photomorphogenic homolog subunit 5 (Arabidopsis)	10.9	Publications

Pathways related to kidney cancer according to GeneDecks:

(show top 50)    (show all 197)

id	Pathway	Score	Top Affiliating Genes
1	Pancreatic cancer20	10.9	RALBP1
2	Signal transduction_PTEN pathway41	10.8	TSC2
3	Transcription Receptor-mediated HIF regulation10	10.3	MAPK1, TSC2, HIF1A
4	Renal cell carcinoma20	10.3	RBX1, VHL, FIGF, FH, CUL2, HIF1A
5	Glioma Invasiveness36	10.3	PLAU, FIGF, PLAUR, VEGFC
6	Immune response MIF-JAB1 signaling10	10.0	RBX1, COPS5, MAPK10, MAPK8, MIF, UCHL1
7	Breast Cancer Regulation by Stathmin136	9.9	FIGF, MAPK10, EGFR
8	Glucose / Energy Metabolism3	9.8	PRKAB1, TSC2, PTEN, CA9, AMACR, ENO2
9	Signal transduction PTEN pathway10	9.8	CDKN1A, MTOR, MAPK1, PTEN, TSC2, PIK3CA
10	Translation _Regulation of EIF4F activity41	9.6	PIK3CA, TSC2, MTOR, MAPK14, MAPK1, EIF4E
11	Immune response_MIF-JAB1 signaling41	9.6	RBX1, MIF, MAPK8, MAPK10, UBC, UCHL1
12	mTOR signaling pathway20	9.6	PIK3CA, HIF1A, EIF4E, FIGF, TSC2, MTOR
13	Transcription_Receptor-mediated HIF regulation41	9.5	PTEN, MTOR, VEGFA, MAPK1, TSC2, PIK3CA
14	Insulin signaling pathway20	9.5	EIF4E, TSC1, TSC2, PRKAB1, MAPK10, MTOR
15	Signal transduction_AKT signaling41	9.4	CDKN1A, MET, TP53, PTEN, TSC1, MTOR
16	Endothelin-1 Signaling Pathway36	9.3	MAPK10, MAPK1, IL2, EGFR, CXCL12, FLT4
17	HIF1Alpha Pathway36	9.1	COPS5, CUL2, TCEB2, HIF1A, TP53, MAPK1
18	Bladder cancer20	9.0	VEGFA, EGFR, DAPK1, MAPK1, TP53, FIGF
19	Akt Signaling36	9.0	CSF2, FLT4, VEGFC, MET, TNF, TSC1
20	mTOR Pathway36	9.0	MAPK10, VEGFC, FIGF, IL2, MAPK8, MAPK14
21	p53 Mediated Apoptosis36	9.0	CXCL12, APAF1, VEGFC, FLT4, FIGF, MET
22	Ras Pathway36	8.9	CXCL12, RALBP1, MAPK1, EGFR, MAPK10, MET
23	ILK Signaling36	8.7	MAPK8, VEGFC, MAPK10, CXCL12, FIGF, HIF1A
24	Prostate cancer20	8.6	PTEN, EGFR, TP53, MAPK1, GSTP1, CDKN1A
25	UVB-Induced MAPK Signaling36	8.6	MAPK8, MAPK14, MAPK10, MAPK1, TP53, EIF4E
26	UVC-Induced MAPK Signaling36	8.5	MAPK8, MAPK14, EGFR, MAPK10, MAPK1, TP53
27	Glioma20	8.5	PIK3CA, MTOR, MAPK1, TP53, CDKN1A, PTEN
28	14-3-3 Induced Intracellular Signaling36	8.5	TSC2, TSC1, MAPK1, MAPK8, MAPK14, MAPK10
29	p70S6K Signaling36	8.4	IL2, VEGFC, FIGF, MET, MAPK8, MAPK14
30	TGF-Beta Pathway36	8.4	FLT4, VEGFC, EGFR, MAPK1, FIGF, MET
31	Focal adhesion20	8.4	FIGF, MAPK1, VEGFA, PTEN, PIK3CA, VEGFC
32	Renin-Angiotensin Pathway36	8.4	MAPK14, MET, IL2, MAPK8, MAPK10, MAPK1
33	Immune response_IL-1 signaling pathway41	8.4	TNF, MAPK10, MAPK14, MAPK8, JUND, UBC
34	Apoptotic Pathways in Synovial Fibroblasts36	8.4	FIGF, EGFR, CXCL12, TP53, IL2, MET
35	MIF Regulation of Innate Immune Cells36	8.4	IL2, CXCL12, TP53, CSF2, MAPK1, MAPK10
36	JAK-STAT Pathway36	8.4	CXCL12, MET, IL2, CUL2, MAPK1, EGFR
37	Cytokine-cytokine receptor interaction20	8.3	EGFR, VEGFC, TNF, CXCR4, CSF2, IL2RB
38	Cellular Apoptosis Pathway36	8.2	APAF1, IL2, MET, FIGF, VEGFC, TP53
39	Molecular Mechanisms of Cancer36	8.2	CXCL12, VEGFC, CDKN1A, MET, IL2, APAF1
40	Toll-like receptor signaling pathway20	8.1	PIK3CA, MAPK8, IFNA1, MAPK1, TNF, MAPK10
41	NFAT in Immune Response36	8.1	EGFR, MAPK10, MAPK1, MAPK14, MAPK8, IL2
42	p53 Signaling36	8.1	PTEN, MAPK8, UBC, CDKN1A, MAPK10, TP53
43	STAT3 Pathway36	8.0	CSF2, MAPK1, TNF, CXCL12, MAPK10, CXCR4
44	PPAR Pathway36	7.9	FLT4, VEGFC, FIGF, MET, MAPK14, MAPK1
45	Chagas disease (American trypanosomiasis)20	7.9	GNAS, MAPK1, MAPK14, MAPK10, MAPK8, IL2
46	p38 Signaling36	7.7	MAPK14, TP53, MET, TNF, EGFR, IL2RB
47	Antioxidant Action of Vitamin-C36	7.7	CXCL12, MAPK8, FIGF, IL2, MAPK1, CSF2
48	MAPK Family Pathway36	7.5	IL2, MET, FIGF, FLT4, VEGFC, EGFR
49	Hepatitis C20	7.4	EGFR, CDKN1A, MAPK8, MAPK14, MAPK10, MAPK1
50	Pathways in cancer20	7.1	VEGFA, TCEB2, EPAS1, MAPK10, HIF1A, EGFR

Compounds related to kidney cancer according to GeneDecks:

(show top 50)    (show all 263)

id	Compound	Score	Top Affiliating Genes
1	egcg32	9.8	MAPK8, MAPK14, MAPK10, PRKAB1
2	threonine32	9.7	CXCL12, DAPK1, GNAS, IL2RB, PAX2, PARK2
3	glucose32	9.4	TCEB2, DES, EPAS1, TSC2, TSC1, EIF4E
4	pge232	9.1	HIF1A, EGFR, PLIN2, PLAUR, PLAU, GNAS
5	rapamycin32 42	9.8	EGFR, CA9, MAPK10, MAPK8, IL2RB, IL2
6	h2o232	8.7	ADPRH, JUND, SDHB, PARK2, RALBP1, SGK1
7	5-aza-2deoxycytidine32	8.5	VHL, PTEN, RASSF1, APAF1, CXCR4, CDKN1A
8	12-o-tetradecanoylphorbol 13-acetate32	8.4	CSF2, UCHL1, CDKN1A, IL2RB, JUND, MAPK14
9	crcs32	8.4	PIK3CA, HIF1A, APAF1, PTEN, TP53, MET
10	ly29400232	8.3	CDKN3, PRKAB1, MAPK8, PIK3CA, TSC2, EIF4E
11	mg 13232 42	9.2	EGFR, MAPK14, MAPK8, PTEN, MAPK1, CDKN1A
12	nitric oxide32 9 18 9	11.1	MET, IL2RB, AQP1, FIGF, MIF, CD274
13	gefitinib32 34 9 9	11.0	VEGFA, EFS, EGFR, MTOR, CDKN1A, CDKN3
14	sb 20358032 42	9.0	CXCR4, CXCL12, PRKAB1, HIF1A, EIF4E, PLAUR
15	n acetylcysteine32	7.9	PRKAB1, HIF1A, EIF4E, EGFR, PLAUR, PLAU
16	imatinib32 34 9 9	10.7	VEGFA, MAPK1, MAPK10, MAPK14, MAPK8, CDKN1A
17	geldanamycin32 9 9	9.6	EGFR, TP53, MAPK1, MAPK10, MAPK14, APAF1
18	okadaic acid32 42	8.6	IL2RB, MAPK10, MAPK14, EIF4E, PLAUR, PLAU
19	arsenite32 18	8.6	OGG1, HIF1A, EIF4E, PLAUR, PTEN, TERF1
20	glycogen32 18	8.6	PIK3CA, ENO2, TSC1, SGK1, VHL, PARK2
21	tamoxifen32 34 9 9	10.6	CA9, IFNA2, IFNA1, MAPK10, IL2RB, IL2
22	doxorubicin32 34 9 9	10.5	DES, HIF1A, EGFR, PIK3CA, RALBP1, MTOR
23	alanine32	7.5	PLAUR, MIF, PTEN, GSTP1, MET, IL2RB
24	5fluorouracil32	7.5	IFNA2, EGFR, TP53, IFNA1, MAPK10, IL2
25	wortmannin32 42	8.4	MTOR, SGK1, PIK3CA, MAPK14, MAPK10, MAPK1
26	adpribose32	7.3	ADPRH, PIK3CA, APAF1, MAPK8, MAPK14, MAPK1
27	estrogen32	7.3	CA9, AMACR, MAPK10, GSTP1, FHIT, FIGF
28	pdtc32	7.2	MAPK14, MAPK1, CP, HIF1A, PLAU, TNF
29	herbimycin a32 42	8.0	TNF, MAPK1, MAPK10, MAPK14, MAPK8, IL2
30	phosphatidylinositol32	6.9	PIK3CA, EFS, CSF2, CXCR4, CXCL12, PRKAB1
31	oxygen32 18	7.9	PTEN, GNAS, MAPK1, MAPK14, MAPK8, IL2RB
32	paraffin32	6.9	PLAUR, PLAU, PTEN, TP53, CA9, AMACR
33	lactate32	6.8	CA9, MAPK10, ENO2, IL2RB, GSTP1, GSTM1
34	phosphoinositide32	6.7	MAPK14, PIK3CA, SGK1, PARK2, MTOR, CDKN3
35	curcumin32	6.7	EGFR, VEGFA, JUND, CDKN1A, MIF, TNF
36	superoxide32 18	7.7	FABP1, APAF1, IL2RB, MET, GSTP1, FH
37	steroid32	6.6	PLAU, PLAUR, CXCL12, TSC2, DES, CXCR4
38	thymidine32 18	7.3	CXCL12, ENO2, IL2RB, IL2, MET, MIF
39	lipid32	6.2	TNF, GNAS, IFNA2, ENO2, FABP2, FABP1
40	dexamethasone32 42 34 9 9	10.2	ADPRH, CP, CSF2, CXCR4, CXCL12, HIF1A
41	actinomycin d32	6.0	VEGFA, VHL, SGK1, PIK3CA, TP53, IFNA1
42	paclitaxel32 34 9 9	9.0	CXCR4, MIF, FLT4, CDKN1A, PARK2, VEGFA
43	pd 98,05932	5.8	PTEN, PIK3CA, VEGFC, TNF, MAPK1, MAPK10
44	genistein32 9 18 9	8.6	CDKN3, MIF, GSTP1, MET, IL2, IL2RB
45	cycloheximide32	5.6	IFNA1, MAPK10, MAPK14, MAPK8, IL2RB, IL2
46	vegf32	5.5	EIF4E, PLIN2, PLAUR, PLAU, TP53, CA9
47	cisplatin32 34 9 9	8.3	CSF2, MAPK8, ENO2, APAF1, IL2RB, IL2
48	retinoic acid32 42 18	7.2	RASSF1, VEGFC, PIK3CA, CP, CSF2, HIF1A
49	tyrosine32	3.8	CSF2, PTEN, CA9, GNAS, AMACR, IFNA2
50	serine32	3.5	HIF1A, EIF4E, EGFR, COPS5, PLAUR, PLAU

Cellular components related to kidney cancer according to GeneDecks:

id	Name	GO ID	Score	Top Affiliating Genes
1	Cul2-RING ubiquitin ligase complex	GO:031462	10.0	TCEB2, CUL2, RBX1
2	focal adhesion	GO:005925	9.9	S100A7, MAPK1, TNS1, TNS3, TNS4, TENC1
3	extracellular space	GO:005615	7.5	PLAU, EGFR, PROM1, CXCL12, CSF2, CP
4	nucleoplasm	GO:005654	7.5	TERF1, CUL2, NDUFA13, HIF1A, TCEB2, OGG1
5	cytoplasm	GO:005737	5.2	DAPK1, DLEC1, PTEN, TERF1, TNS4, TNS1
6	cytosol	GO:005829	4.3	EPAS1, MAPK8, MAPK14, MAPK10, MAPK1, GNAS

Biological processes related to kidney cancer according to GeneDecks:

(show all 45)

id	Name	GO ID	Score	Top Affiliating Genes
1	positive regulation of mast cell chemotaxis	GO:060754	10.6	FIGF, VEGFC, VEGFA
2	positive chemotaxis	GO:050918	10.5	VEGFA, VEGFC, MIF, FIGF, TSC2
3	induction of positive chemotaxis	GO:050930	10.4	CXCL12, FIGF, VEGFC, VEGFA
4	negative regulation of cell size	GO:045792	10.3	TSC1, PTEN, MTOR
5	positive regulation of endothelial cell proliferation	GO:001938	10.2	CXCL12, HIF1A, FLT4, MTOR, VEGFA
6	vascular endothelial growth factor receptor signaling pathway	GO:048010	10.1	MAPK14, FIGF, FLT4, VEGFC, VEGFA
7	insulin receptor signaling pathway	GO:008286	9.9	PRKAB1, TSC2, TSC1, EIF4E, MAPK1, MTOR
8	induction of apoptosis by intracellular signals	GO:008629	9.9	CUL2, TP53, MAPK8, APAF1, CDKN1A
9	embryonic placenta development	GO:001892	9.9	EPAS1, CSF2, HIF1A, EGFR
10	cell cycle arrest	GO:007050	9.8	PRKAB1, TSC2, TSC1, CUL2, TP53, CDKN3
11	regulation of transcription from RNA polymerase II promoter in response to hypoxia	GO:061418	9.8	EPAS1, TCEB2, HIF1A, CUL2, CA9, UBC
12	cellular response to stress	GO:033554	9.8	EPAS1, TCEB2, HIF1A, CUL2, CA9, AQP1
13	positive regulation of fibroblast proliferation	GO:048146	9.7	CDKN1A, MIF, AQP1, EGFR
14	regulation of sequence-specific DNA binding transcription factor activity	GO:051090	9.6	MAPK1, MAPK10, MAPK14, MAPK8, SGK1
15	angiogenesis	GO:001525	9.5	EPAS1, HIF1A, PTEN, MAPK14, FIGF, S100A7
16	positive regulation of peptidyl-serine phosphorylation	GO:033138	9.5	TNF, MET, MIF, VEGFA, PIK3CA
17	regulation of apoptotic process	GO:042981	9.5	DAPK1, TP53, APAF1, UBC, UNC5B, UNC5A
18	protein kinase B signaling cascade	GO:043491	9.4	TSC2, PTEN, TNF, PAX2, PIK3CA
19	chemotaxis	GO:006935	9.4	CXCL12, PLAUR, PLAU, MAPK1, MAPK14, RALBP1
20	negative regulation of gene expression	GO:010629	9.3	PLAUR, TNF, IFNA2, MIF, CDKN1A
21	positive regulation of cell proliferation	GO:008284	9.3	CSF2, EGFR, PTEN, TNS3, FABP1, IL2
22	response to hypoxia	GO:001666	9.3	EPAS1, CXCR4, CXCL12, HIF1A, TNF, FIGF
23	response to stress	GO:006950	9.3	EGFR, PHF17, MAPK1, MAPK14, MAPK8, UCHL1
24	cellular response to hypoxia	GO:071456	9.2	RBX1, EPAS1, TCEB2, HIF1A, CUL2, TP53
25	Ras protein signal transduction	GO:007265	9.2	CDKN1A, MAPK14, MAPK1, TP53, RASSF1
26	fibroblast growth factor receptor signaling pathway	GO:008543	9.2	TSC2, PTEN, MAPK1, MTOR, UBC, PIK3CA
27	stress-activated MAPK cascade	GO:051403	9.0	MAPK1, MAPK10, MAPK14, MAPK8, UBC
28	MyD88-independent toll-like receptor signaling pathway	GO:002756	9.0	MAPK1, MAPK10, MAPK14, MAPK8, UBC
29	TRIF-dependent toll-like receptor signaling pathway	GO:035666	8.9	MAPK1, MAPK10, MAPK14, MAPK8, UBC
30	anti-apoptosis	GO:006916	8.9	DAPK1, TNF, IL2, GSTP1, BAG3, UBC
31	toll-like receptor 1 signaling pathway	GO:034130	8.9	MAPK1, MAPK10, MAPK14, MAPK8, UBC
32	induction of apoptosis	GO:006917	8.9	NDUFA13, DAPK1, PTEN, TERF1, TNF, IFNA2
33	toll-like receptor 3 signaling pathway	GO:034138	8.9	MAPK1, MAPK10, MAPK14, MAPK8, UBC
34	epidermal growth factor receptor signaling pathway	GO:007173	8.8	TSC2, EGFR, PTEN, MAPK1, MTOR, UBC
35	toll-like receptor 2 signaling pathway	GO:034134	8.8	MAPK1, MAPK10, MAPK14, MAPK8, UBC
36	nerve growth factor receptor signaling pathway	GO:048011	8.8	TSC2, PTEN, MAPK1, MAPK14, MAPK8, MTOR
37	toll-like receptor signaling pathway	GO:002224	8.7	MAPK1, MAPK10, MAPK14, MAPK8, UBC
38	negative regulation of cell proliferation	GO:008285	8.7	TSC2, TSC1, RNF139, CUL2, DLEC1, PTEN
39	MyD88-dependent toll-like receptor signaling pathway	GO:002755	8.6	MAPK1, MAPK10, MAPK14, MAPK8, UBC
40	response to drug	GO:042493	8.5	PLIN2, TERF1, TNF, ENO2, AQP1, MET
41	blood coagulation	GO:007596	8.3	PLAUR, PLAU, TP53, GNAS, IFNA2, MAPK1
42	activation of MAPK activity	GO:000187	8.2	CXCR4, TNF, MAPK1, MAPK10, MAPK14, MET
43	signal transduction	GO:007165	7.7	PLAU, PLAUR, EGFR, HIF1A, PRKAB1, CXCL12
44	negative regulation of apoptotic process	GO:043066	7.3	TP53, TNF, PTEN, PLAUR, EGFR, CXCL12
45	apoptotic process	GO:006915	7.2	TP53, TNF, TNS4, PTEN, DAPK1, PHF17

Molecular functions related to kidney cancer according to GeneDecks:

id	Name	GO ID	Score	Top Affiliating Genes
1	chemoattractant activity	GO:042056	10.1	FIGF, MIF, VEGFC, VEGFA
2	glutathione transferase activity	GO:004364	9.4	GSTM1, GSTM3, GSTP1, GSTT1
3	chaperone binding	GO:051087	9.3	CP, TSC1, TP53, BAG3, PARK2
4	ubiquitin protein ligase binding	GO:031625	9.2	CXCR4, TCEB2, HIF1A, SPOP, CUL2, TP53
5	protein heterodimerization activity	GO:046982	8.6	HIF1A, EGFR, TERF1, TP53, ENO2, MET
6	protein binding	GO:005515	1.1	EPAS1, COPS5, PLAUR, PLAU, SPOP, CUL2